Quantum BioPharma Ltd. (QNTM)

CA — Healthcare Sector
Peers: RVPH  ANVS  CPIX  PYPD  RMTI  RNTX  CELU  BCAB  ATNM  EVAX 

Automate Your Wheel Strategy on QNTM

With Tiblio's Option Bot, you can configure your own wheel strategy including QNTM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
QNTM
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”) a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that management will attend the Sidoti Micro-Cap Conference and the A.G.P. Virtual Healthcare Conference in May 2025.

Read More
image for news Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
QNTM
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that dosing of drug has completed in 90-day oral toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS) for Multiple Sclerosis (“MS”). These studies were commissioned to provide data to support an IND application with the US FDA.

Read More
image for news Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
Quantum BioPharma Ltd. (QNTM) Business Update Conference Call Transcript
QNTM
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral

Call Start: 16:30 January 1, 0000 4:57 PM ET Quantum BioPharma Ltd. (NASDAQ:QNTM ) Business Update Conference Call May 6, 2025, 04:30 PM ET Company Participants Zeeshan Saeed - Founder, Chief Executive Officer, President and Executive Co-Chair Jason Sawyer - Head of Finance and M&A Conference Call Participants Operator Greetings, and welcome to the Quantum BioPharma Business Update Conference Call.

Read More
image for news Quantum BioPharma Ltd. (QNTM) Business Update Conference Call Transcript
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
QNTM
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Kevin Malone as an advisor to the Board of Directors. Mr. Malone brings a vast wealth of successful stock trading experience, especially in manipulated companies, from his years of wealth management.

Read More
image for news Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
QNTM
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

Alcohol Detoxification and Anti-Hangover Beverage (Available on amazon.com and unbuzzd.com ) to be Distributed by FUSION in Puerto Rico and Caribbean Region TORONTO, April 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), today announced its licensee – Celly Nutrition Corporation (“Celly Nutrition”), the company behind unbuzzd™ – the beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms – is launching unbuzzd in Puerto Rico with distribution partner FUSION Distribution Group, a leading distributor of health-conscious food and beverage offerings across Puerto Rico, the Caribbean, and parts …

Read More
image for news Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
QNTM
Published: March 28, 2025 by: Accesswire
Sentiment: Neutral

Completion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets TORONTO, ONTARIO / ACCESS Newswire / March 28, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"),has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.

Read More
image for news Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
QNTM
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

TORONTO, March 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,500,000 worth of Bitcoin (BTC) and other cryptocurrencies, growing and increasing its crypto assets as part of its strategic efforts. This brings the total amount of Bitcoin (BTC), and other cryptocurrencies purchased to USD $3,500,000. As previously announced, the company will continue to allow for future financings and other transactions to be carried out in cryptocurrency.

Read More
image for news Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies

About Quantum BioPharma Ltd. (QNTM)

  • IPO Date 2018-06-08
  • Website https://www.quantumbiopharma.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Lakshmi Kotra
  • Employees None

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.